An investigational new drug application was filed by Tiziana Life Sciences with the FDA for an early-stage study of enteric-coated capsules of foralumab in healthy volunteers. The drug is being assessed as a treatment for patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Tiziana files IND for oral formulation of drug for NASH, liver disease
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.